Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Ying-Hsiang Lee"'
Autor:
Chun-Lin Wang, Chiu-Chi Wei, Cheng-Ting Tsai, Ying-Hsiang Lee, Lawrence Yu-Min Liu, Kang-Ying Chen, Yu-Jen Lin, Po-Lin Lin
Publikováno v:
BioMedical Engineering OnLine, Vol 22, Iss 1, Pp 1-14 (2023)
Abstract Background Exercise electrocardiography (ECG) is a noninvasive test aiming at producing ischemic changes. However, resting ECG cannot be adopted in diagnosing myocardial ischemia till ST-segment depressions. Therefore, this study aimed to de
Externí odkaz:
https://doaj.org/article/c42728eeed6d4bd198f7568ed9bc5242
Autor:
Hsin‐Ti Huang, Jin‐Long Huang, Po‐Lin Lin, Ying‐Hsiang Lee, Chien‐Yi Hsu, Fa‐Po Chung, Chia‐Te Liao, Wei‐Ru Chiou, Wen‐Yu Lin, Huai‐Wen Liang, Hung‐Yu Chang
Publikováno v:
ESC Heart Failure, Vol 9, Iss 6, Pp 3825-3835 (2022)
Abstract Aims Sacubitril/valsartan (SAC/VAL) has been used in patients with heart failure and reduced ejection fraction (HFrEF), and cardiac resynchronization therapy (CRT) could benefit the HFrEF patients with wide QRS durations. This study aimed to
Externí odkaz:
https://doaj.org/article/6a3b8f50ef5945be946595f1410a5401
Autor:
Po-Lin Lin, Ping-Yen Lin, Han-Ping Huang, Hamideh Vaezi, Lawrence Yu-Min Liu, Ying-Hsiang Lee, Chun-Che Huang, Ten-Fang Yang, Long Hsu, Chang Francis Hsu
Publikováno v:
BioMedical Engineering OnLine, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background The current method to evaluate the autonomic balance after renal denervation (RDN) relies on heart rate variability (HRV). However, parameters of HRV were not always predictive of response to RDN. Therefore, the complexity and dis
Externí odkaz:
https://doaj.org/article/5fa2eb2d8a9c45f09c0e10ecaa720b84
Autor:
Wei-Ru Chiou, Po-Lin Lin, Chun-Che Huang, Jen-Yu Chuang, Lawrence Yu-Min Liu, Min-I Su, Feng-Ching Liao, Jen-Yuan Kuo, Cheng-Ting Tsai, Yih-Jer Wu, Kuang-Te Wang, Ying-Hsiang Lee
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The current treatment paradigm for atrial fibrillation (AF) prioritizes rate control over rhythm control; however, rhythm control has shown benefits over other AF strategies. This study compares the outcomes of rivaroxaban with and without c
Externí odkaz:
https://doaj.org/article/43167e11bf1848cc8777040e625286bb
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 20, p 6686 (2023)
Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial, demonstrating safety in the Asian population. It remains unclear whether treatment with reduced-dose versus full-dose rivaroxaban (20 mg/15 mg) is associated with all-cau
Externí odkaz:
https://doaj.org/article/4efe6e47249f4fafa15536c1bd763bd9
Autor:
Chia‐Te Liao, Jin‐Long Huang, Huai‐Wen Liang, Fa‐Po Chung, Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Wen‐Yu Lin, Chien‐Yi Hsu, Hung‐Yu Chang
Publikováno v:
ESC Heart Failure, Vol 8, Iss 5, Pp 4199-4210 (2021)
Abstract Aims Ivabradine has been used in patients who have chronic heart failure (HF) with reduced ejection fraction (HFrEF) and concomitant sinus heart rate ≥70 bpm. This administration for acute HFrEF remains a concern. This study used a real‐
Externí odkaz:
https://doaj.org/article/1a4b0041385f427cb641ad8366560ce5
Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
Autor:
Chien-Yi Hsu, Hung-Yu Chang, Chieh-Ju Chao, Wei-Ru Chiou, Po-Lin Lin, Fa-Po Chung, Wen-Yu Lin, Jin-Long Huang, Huai-Wen Liang, Chia-Te Liao, Ying-Hsiang Lee
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
ObjectiveThe aim of this study was to investigate the application of sacubitril/valsartan in clinical practice and the utility of PREDICT-HF score for outcome prediction in Asian heart failure patients with difference risk profiles.MethodsThe TAROT-H
Externí odkaz:
https://doaj.org/article/c232290e75e540bf8ca8f7ae50593f62
Autor:
Po-Lin Lin MD, Ying-Hsiang Lee MD, Lawrence Yu-Min Liu MD, PhD, Cheng-Ting Tsai MD, Ten-Fang Yang MD, Wei-Ru Chiou MD, Mu-Yang Hsieh MD, Hung-Yu Chang MD, Chun-Che Huang PhD
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics, Vol 27 (2022)
Aim: Changes in QRS duration in patients with heart failure with reduced ejection fraction (HFrEF) after sacubitril/valsartan therapy is not fully understood. This study aimed to assess the association of duration of HFrEF diagnosis with electrocardi
Externí odkaz:
https://doaj.org/article/29a250c55e2e43fc8d71bb243352f2f5
Autor:
Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Jin‐Long Huang, Wen‐Yu Lin, Chia‐Te Liao, Fa‐Po Chung, Huai‐Wen Liang, Chien‐Yi Hsu, Hung‐Yu Chang
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1204-1215 (2021)
Abstract Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medicati
Externí odkaz:
https://doaj.org/article/8f6b2277d17744ba92d26c22971b37d7
Autor:
Wei-Ru Chiou, Po-Lin Lin, Chun-Che Huang, Jen-Yu Chuang, Lawrence Yu-Min Liu, Min-I Su, Feng-Ching Liao, Jen-Yuan Kuo, Cheng-Ting Tsai, Yih-Jer Wu, Kuang-Te Wang, Ying-Hsiang Lee
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/dfe4a656758348268dd79ad988c910bc